Clinical trial
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
NCT00144599 · Chugai Pharmaceutical, Industry · Completed
Key facts
| NCT number | NCT00144599 |
|---|---|
| Title | Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) |
| Official title | A Double-Blind, Phase III Study to Evaluate the Efficacy, Safety and PK of MRA in Patients With sJIA |
| Lead sponsor | Chugai Pharmaceutical, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Systemic Juvenile Idiopathic Arthritis |
| Intervention type | Drug |
| Interventions | MRA(Tocilizumab), placebo |
| Enrollment | 56 |
| Start date | May 1, 2004 |
| Completion | Oct 1, 2005 |
| First posted | Sep 5, 2005 |
| Last update posted | Jul 30, 2008 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: